Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20

2:47

Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

Renal Cell Carcinoma
Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20

Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.